The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial
Open accessAbstract
Importance: Robot-assisted radical cystectomy is being performed with increasing frequency, but it is unclear whether total intracorporeal surgery improves recovery compared with open radical cystectomy for bladder cancer. Objectives: To compare recovery and morbidity after robot-assisted radical cystectomy with intracorporeal reconstruction vs open radical cystectomy. Design, Setting, and Participants: Randomized clinical trial of patients with nonmetastatic bladder cancer recruited at 9 sites in the UK, from March 2017-March 2020. Follow-up was conducted at 90 days, 6 months, and 12 months, with final follow-up on September 23, 2021. Interventions: Participants were randomized to receive robot-assisted radical cystectomy with intracorporeal reconstruction (n = 169) or open radical cystectomy (n = 169). Main Outcomes and Measures: The primary outcome was the number of days alive and out of the hospital within 90 days of surgery. There were 20 secondary outcomes, including complications, quality of life, disability, stamina, activity levels, and survival. Analyses were adjusted for the type of diversion and center. Results: Among 338 randomized participants, 317 underwent radical cystectomy (mean age, 69 years; 67 women [21%]; 107 [34%] received neoadjuvant chemotherapy; 282 [89%] underwent ileal conduit reconstruction); the primary outcome was analyzed in 305 (96%). The median number of days alive and out of the hospital within 90 days of surgery was 82 (IQR, 76-84) for patients undergoing robotic surgery vs 80 (IQR, 72-83) for open surgery (adjusted difference, 2.2 days [95% CI, 0.50-3.85]; P = .01). Thromboembolic complications (1.9% vs 8.3%; difference, -6.5% [95% CI, -11.4% to -1.4%]) and wound complications (5.6% vs 16.0%; difference, -11.7% [95% CI, -18.6% to -4.6%]) were less common with robotic surgery than open surgery. Participants undergoing open surgery reported worse quality of life vs robotic surgery at 5 weeks (difference in mean European Quality of Life 5-Dimension, 5-Level instrument scores, -0.07 [95% CI, -0.11 to -0.03]; P = .003) and greater disability at 5 weeks (difference in World Health Organization Disability Assessment Schedule 2.0 scores, 0.48 [95% CI, 0.15-0.73]; P = .003) and at 12 weeks (difference in WHODAS 2.0 scores, 0.38 [95% CI, 0.09-0.68]; P = .01); the differences were not significant after 12 weeks. There were no statistically significant differences in cancer recurrence (29/161 [18%] vs 25/156 [16%] after robotic and open surgery, respectively) and overall mortality (23/161 [14.3%] vs 23/156 [14.7%]), respectively) at median follow-up of 18.4 months (IQR, 12.8-21.1). Conclusions and Relevance: Among patients with nonmetastatic bladder cancer undergoing radical cystectomy, treatment with robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy resulted in a statistically significant increase in days alive and out of the hospital over 90 days. However, the clinical importance of these findings remains uncertain. Trial Registration: ISRCTN Identifier: ISRCTN13680280; ClinicalTrials.gov Identifier: NCT03049410.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience
Clavien, P. A., Barkun, J., de Oliveira, M. L., Vauthey, J. N., Dindo, D., Schulick, R. D., de Santibañes, E., Pekolj, J., Slankamenac, K., Bassi, C., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b13ca2 · Cited by 11,482
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
(2010) · Virtual Defense Library (Ministerio de Defensa) · Cited by 1,530
Jayne, D., Pigazzi, A., Marshall, H., Croft, J., Corrigan, N., Copeland, J., Quirke, P., West, N., Rautio, T., Thomassen, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7219 · Cited by 1,450
Rikli, R. E., & Jones, C. J. (2013) · The Gerontologist · doi:10.1093/geront/gns071 · Cited by 1,101
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 929
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
Cumberbatch, M. G. K., Jubber, I., Black, P. C., Esperto, F., Figueroa, J. D., Kamat, A. M., Kiemeney, L., Lotan, Y., Pang, K., Silverman, D. T., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.001 · Cited by 820
Self-citationParekh, D. J., Reis, I. M., Castle, E. P., Gonzalgo, M. L., Woods, M. E., Svatek, R. S., Weizer, A. Z., Konety, B. R., Tollefson, M., Krupski, T. L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30996-6 · Cited by 790
Yaxley, J. W., Coughlin, G. D., Chambers, S. K., Occhipinti, S., Samaratunga, H., Zajdlewicz, L., Dunglison, N., Carter, R., Williams, S., Payton, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30592-x · Cited by 715
Methods for Analysing and Reporting EQ-5D Data
Devlin, N., Parkin, D., & Janssen, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-47622-9 · Cited by 371
Ozalevli, S., Ozden, A., Itil, O., & Akkoclu, A. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2006.05.007 · Cited by 330
American Journal of Human Biology
(2006) · American Journal of Human Biology · doi:10.1002/(issn)1520-6300 · Cited by 266
McConnell, M. V., Shcherbina, A., Pavlovic, A., Homburger, J. R., Goldfeder, R. L., Waggot, D., Cho, M. K., Rosenberger, M. E., Haskell, W. L., Myers, J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4395 · Cited by 239
Days Alive and Out of Hospital: Validation of a Patient-centered Outcome for Perioperative Medicine
Jerath, A., Austin, P. C., & Wijeysundera, D. N. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002701 · Cited by 220
Noon, A. P., Albertsen, P. C., Thomas, F., Rosario, D. J., & Catto, J. W. F. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.106 · Cited by 181
Self-citationQuality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes
Catto, J. W. F., Downing, A., Mason, S., Wright, P., Absolom, K., Bottomley, S., Hounsome, L., Hussain, S., Varughese, M., Raw, C., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.01.032 · Cited by 172
Self-citationRecurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer
Nguyen, D. P., Al Hussein Al Awamlh, B., Wu, X., O’Malley, P., Inoyatov, I. M., Ayangbesan, A., Faltas, B. M., Christos, P. J., & Scherr, D. S. (2015) · European Urology · doi:10.1016/j.eururo.2015.02.003 · Cited by 171
Vetterlein, M. W., Klemm, J., Gild, P., Bradtke, M., Soave, A., Dahlem, R., Fisch, M., & Rink, M. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.011 · Cited by 139
Catto, J. W. F., Gordon, K., Collinson, M., Poad, H., Twiddy, M., Johnson, M. I., Jain, S., Chahal, R., Simms, M. S., Dooldeniya, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01665 · Cited by 123
Self-citationMacfarlane, D., Chou, K., Cheng, Y., & Chi, I. (2006) · American Journal of Human Biology · doi:10.1002/ajhb.20503 · Cited by 109
Williams, S. B., Shan, Y., Jazzar, U., Mehta, H. B., Baillargeon, J., Huo, J. S., Senagore, A. J., Orihuela, E., Tyler, D. S., Swanson, T. A., et al. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2018.1680 · Cited by 102
Catto, J. W. F., Khetrapal, P., Ambler, G., Sarpong, R., Khan, M. S., Tan, M., Feber, A., Dixon, S., Goodwin, L., Williams, N. R., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020500 · Cited by 90
Self-citationO’Keeffe, A. G., Ambler, G., & Barber, J. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0426-1 · Cited by 75
Self-citationGómez-Olivé, F. X., Schröders, J., Aboderin, I., Byass, P., Chatterji, S., Davies, J. I., Debpuur, C. Y., Hirve, S. S., Hodgson, A., Juvekar, S. K., et al. (2017) · BMJ Global Health · doi:10.1136/bmjgh-2017-000508 · Cited by 41
Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials
Gamper, E., Musoro, J. Z., Coens, C., Stelmes, J., Falato, C., Grøenvold, M., Velikova, G., Cocks, K., Flechtner, H., King, M. T., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08609-7 · Cited by 28
Catto, J. W. F., Khetrapal, P., Ambler, G., Sarpong, R., Potyka, I., Khan, M. S., Tan, M., Feber, A., Bourke, L., Noon, A. P., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.05.008 · Cited by 25
Self-citation
Cited by
Alfred Witjes, J., Max Bruins, H., Carrión, A., Cathomas, R., Compérat, E., Efstathiou, J. A., Fietkau, R., Gakis, G., Lorch, A., Martini, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.08.016 · Cited by 648
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Advances in diagnosis and treatment of bladder cancer
Lopez-Beltran, A., Cookson, M. S., Guercio, B. J., & Cheng, L. (2024) · BMJ · doi:10.1136/bmj-2023-076743 · Cited by 496
Metadata
- Authors
- Catto, J. W. F., Khetrapal, P., Ricciardi, F., Ambler, G., Williams, N. R., Al-Hammouri, T., Khan, M. S., Thurairaja, R., Nair, R., Feber, A., Dixon, S., Nathan, S., Briggs, T., Sridhar, A., Ahmad, I., Bhatt, J., Charlesworth, P., Blick, C., Cumberbatch, M. G., Hussain, S. A., Kotwal, S., Koupparis, A., McGrath, J., Noon, A. P., Rowe, E., Vasdev, N., Hanchanale, V., Hagan, D., Brew-Graves, C., Kelly, J. D., iROC Study Team, Groves, E. R., Goodwin, L., Willson, J., Ravencroft, P., Kennish, S., Rosario, D. J., Torrington, C., Nair, R., Thurairaja, R., Amery, S., Chatterton, K., Broadhead, S., Hendry, D., Zreik, A., Jain, S., Prescott, S., Roberts, H., Morgan, A., Main, C., Bedford, E., Wiseman, L., Mpofu, B., Daisey, C., Donachie, M., Aning, J., Johnson, L., Brain, C., Shiridzinomwa, C., Ebon, M., Hampson, A., Schimmel, R., Horsley, S., Nembhard, S., Collins, C., Gilmore, J., Wilson, F., Peacock, L., Lim, S., Gabriel, R., Sarpong, R., & Tan, M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2022-06-07
- Volume
- 327
- Issue
- 21
- Pages
- 2092
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4280542446
- Cited by
- 345
- References
- 27
- FWCI
- 60.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.